Endocrine Late Effects After Cancer: Thyroid, Bone, Gonadal, and Metabolic Follow-Up
Endocrine late effects are common, slow, and easy to attribute to something else. A practical panel-by-panel follow-up cadence for survivors and the clinicians carrying their charts.
Endocrine late effects are the quietest category in survivorship. They arrive slowly, present as fatigue or mood change or a stalled growth curve, and get attributed to almost anything else. They are also among the most treatable late effects once identified, which makes the miss expensive.
Thyroid
Neck, mantle, or cranial radiation raises the risk of both hypothyroidism and thyroid nodules, sometimes many years out. A periodic thyroid function panel plus a deliberate neck examination is the standard pattern, with imaging reserved for palpable or symptomatic findings.
Gonadal and fertility
Alkylating agents, pelvic radiation, and transplant conditioning can cause premature gonadal insufficiency in any sex. The clinical signal is often a symptom cluster — cycle change, low libido, fatigue, mood change — that is easy to attribute to survivorship generally.
Fertility counseling deserves an explicit revisit at any life-stage change rather than a single conversation at the end of treatment.
Bone density
Corticosteroids, gonadal insufficiency, methotrexate, and transplant all reduce bone density. Survivors frequently reach clinically meaningful bone loss decades earlier than the general population, and the screening decision is usually driven by the exposure list rather than by age.
Adrenal and pituitary
Cranial or total-body irradiation can affect the hypothalamic-pituitary axis, producing growth-hormone, adrenal, or gonadotropin deficits that appear years later. Growth trajectory in younger survivors and unexplained fatigue or orthostatic symptoms in adults are the practical triggers for evaluation.
Metabolic
Insulin resistance, dyslipidemia, and central adiposity cluster after several treatment exposures and compound cardiovascular risk that is already elevated by anthracycline or chest-radiation history. This is the axis where endocrine follow-up and cardio-oncology surveillance visibly converge.
Frequently asked questions
- Who should own endocrine follow-up in a shared care model?
- Primary care can own the routine panels and the recognition pattern, escalating to endocrinology for abnormal axes, pituitary questions, or fertility planning. What matters is that the ownership is written down rather than assumed.
- How often should the panel repeat?
- Cadence depends on exposure and prior results. The clinician workspace generates an exposure-indexed schedule rather than a single universal interval, because a survivor with cranial radiation and one with an alkylator exposure need different calendars.
- Is fatigue enough to trigger a workup?
- Persistent, unexplained fatigue in a survivor with a relevant exposure is a reasonable trigger for thyroid, gonadal, and adrenal evaluation before attributing it to deconditioning or mood.